Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01274533 · ClinicalTrials.gov registry record · Phase 2
Lenalidomide in HTLV-1 Adult T-Cell Leukemia
A Phase 2 study of Adult T-cell Leukemia/Lymphoma, sponsored by Columbia University.
- Completed
- Registry status
- Phase 2
- Development phase
- 4
- Enrollment target
- 1
- Study location
NCT01274533 is a Phase 2 study of Adult T-cell Leukemia/Lymphoma that has completed, run by Columbia University. The registered enrollment target is 4 participants, below the 50-participant average among 7 other Adult T-cell Leukemia/Lymphoma trials with a reported enrollment target (92% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01274533, a Phase 2 study of Adult T-cell Leukemia/Lymphoma, has completed, sponsored by Columbia University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 4 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a research study for subjects who have been diagnosed with Adult T cell Leukemia/Lymphoma, a rare and aggressive peripheral T cell neoplasm caused by the virus HTLV1. Currently, there is no accepted standard therapy for this disease. The purpose of this research study is to evaluate the use of the investigational drug lenalidomide in the treatment of Adult T cell Leukemia/Lymphoma. Lenalidomide is a drug that alters the immune system and it may also interfere with the development of tiny blood vessels that help support tumor growth. Therefore, in theory, it may reduce or prevent the growth of cancer cells. Lenalidomide is approved by the Food and Drug Administration (FDA) for the treatment of specific types of myelodysplastic syndrome (MDS) and in combination with dexamethasone for patients with multiple myeloma (MM) who have received at least 1 prior therapy. MDS and MM are cancers of the blood. It is currently being tested in a variety of cancer conditions. In this case it is considered experimental.
Conditions Studied
Interventions
- DRUG Lenalidomide
Study Locations (1)
New York
- Columbia University Medical Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2010-12 |
| Est. Completion | 2013-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01274533
The ClinicalTrials.gov registry entry for NCT01274533 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 50-participant average among 7 other Adult T-cell Leukemia/Lymphoma trials with a reported enrollment target (92% lower). The listed sponsor is Columbia University, which has 958 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Adult T-cell Leukemia/Lymphoma appearing as the primary indexed condition, and to 1 intervention - of which Lenalidomide is the first listed.
NCT01274533 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT01274533 about?
NCT01274533 is a clinical study titled "Lenalidomide in HTLV-1 Adult T-Cell Leukemia". This is a research study for subjects who have been diagnosed with Adult T cell Leukemia/Lymphoma, a rare and aggressive peripheral T cell neoplasm caused by the virus HTLV1. Currently, there is no accepted standard therapy for this disease. The purpose of this research study is to evaluate the use ...
What is the current status of trial NCT01274533?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 4 participants. The study started on 2010-12. Estimated completion is 2013-05.
What conditions does trial NCT01274533 study?
This clinical trial studies the following conditions: Adult T-cell Leukemia/Lymphoma.
What interventions are being tested in trial NCT01274533?
The interventions under investigation include: Lenalidomide (DRUG).
Who is sponsoring clinical trial NCT01274533?
This trial is sponsored by Columbia University, which has 958 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01274533 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Adult T-cell Leukemia/Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Ruxolitinib Maintenance Post-Hematopoietic Stem Cell Transplant T-Cell Lymphoma
RECRUITING · Phase 2
-
Two Step Haplo With Radiation Conditioning
RECRUITING · Phase 2
-
BV-CHEP Chemotherapy for Adult T-cell Leukemia or Lymphoma
ACTIVE NOT RECRUITING · Phase 2
-
Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With CD30-Positive Peripheral T-cell Lymphoma
ACTIVE NOT RECRUITING · Phase 2
-
Valemetostat Tosylate (DS-3201b), an Enhancer of Zeste Homolog (EZH) 1/2 Dual Inhibitor, for Relapsed/Refractory Peripheral T-Cell Lymphoma (VALENTINE-PTCL01)
ACTIVE NOT RECRUITING · Phase 2
-
Azacitidine and Abatacept in Relapsed or Refractory T-Cell Lymphoma
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.